Vaxcyte (PCVX) said Wednesday its ongoing phase 2 study assessing VAX-31 for the prevention of invasive pneumococcal disease in infants is advancing to its second and final stage.
The company said participants who received VAX-31 in the first stage will continue the standard dosing regimen as part of the second stage.
Vaxcyte said it expects to release topline data from the study's primary three-dose immunization series in the middle of next year, followed by topline data from the booster dose about nine months later.
In infants, the VAX-31 was designed to cover about 94% of invasive pneumococcal disease and roughly 93% of acute otitis media caused by streptococcus pneumoniae in children under five years old in the United States.
Shares of Vaxcyte were up nearly 3% in recent trading.
Price: 88.88, Change: +2.37, Percent Change: +2.73
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。